|
|
Cardiovascular Exchange Summit 2011
|
|
|
|
Cardiovascular mortality in haemodialysis patients
|
|
|
|
Causes of death in dialysis patients
|
|
|
|
Serum cholesterol and relative risk of death
|
|
|
|
Proportional effects on MAJOR VASCULAR EVENTS
|
|
|
|
SHARP: Rationale
|
|
|
|
SHARP: Eligibility
|
|
|
|
SHARP: Assessment of LDL-lowering
|
|
|
|
SHARP: Main outcomes
|
|
|
|
SHARP: Baseline characteristics
|
|
|
|
RENAL STATUS
|
|
|
|
LIPID PROFILE at initial randomization
|
|
|
|
SHARP: Compliance and LDL-C reduction at study midpoint
|
|
|
|
SHARP: Compliance and LDL-C reduction at study midpoint
|
|
|
|
SHARP: Major Atherosclerotic Events
|
|
|
|
CTT: Effects on Major Atherosclerotic Events
|
|
|
|
CTT: Effects on Major Atherosclerotic Events
|
|
|
|
CTT: Effects on Major Atherosclerotic Events
|
|
|
|
SHARP: Major Atherosclerotic Events
|
|
|
|
SHARP: Cause-specific mortality
|
|
|
|
SHARP: Renal outcomes
|
|
|
|
SHARP: estimated rate of change in eGFR
|
|
|
|
SHARP: Cancer incidence
|
|
|
|
SHARP: Safety
|
|
|
|
SHARP: Conclusions
|
|
Deel deze pagina met collega's en vrienden: